Healthcare Purchasing News
  • Magazine
  • Continuing Education
  • Webinars
  • Whitepapers
  • Videos
  • Events
  • Hall of Fame
  • Advertise
  • Source Guide
  • Subscribe
  • Sourcing & Logistics
  • Sterile Processing
  • Surgical & Critical Care
  • Patient Satisfaction
  • Infection Prevention
  • EVS & Facility Services
  • Healthcare IT
  • Regulatory
  • Topics
    Sourcing & LogisticsSterile ProcessingSurgical & Critical CarePatient SatisfactionInfection PreventionEVS & Facility ServicesHealthcare ITRegulatory
    Resources
    HPN Source GuideContinuing EducationWebinarsWhitepapersVideosEventsHall of FameAdvertiseAd Specs
    User Tools
    SubscribeContact UsAbout UseNewsletterMagazinesPrivacy PolicyTerms & Conditions
    https://www.facebook.com/hpnonline
    https://www.linkedin.com/company/healthcare-purchasing-news/
    https://twitter.com/HPN_Online
    1. Surgical/Critical Care

    New formulation allows for uninterrupted treatment for PAH patients temporarily unable to take oral therapy

    Aug. 2, 2021
    Photo by Marcelo Leal on Unsplash
    Marcelo Leal 6pc Gtj Duf6 M Unsplash

    Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved UPTRAVI (selexipag) injection for intravenous (IV) use for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) in adult patients with WHO functional class (FC) II–III, who are temporarily unable to take oral therapy.

    UPTRAVI IV is a therapeutic option that will allow patients to avoid short-term treatment interruptions and stay on UPTRAVI® therapy, as uninterrupted treatment is considered key for individuals with PAH. UPTRAVI® tablets were first approved by the FDA in 2015 to delay disease progression and reduce the risk of hospitalization for PAH.

    “Given the progressive nature of this disease, maintaining treatment is important to help control PAH. However, there are times where patients may be unable to take oral medications. For patients on UPTRAVI, bridging short-term temporary interruptions of UPTRAVI tablets with UPTRAVI IV may maintain the treatment effect and avoid the need to change therapy or re-titrate UPTRAVI tablets after re-initiation,” said Kelly Chin, M.D., UPTRAVI IV study senior author and Associate Professor of Internal Medicine and Director of the Pulmonary Hypertension Program at The University of Texas Southwestern Medical Center.

    The FDA approval is based upon the findings from a prospective, multi-center, open-label single sequence cross-over Phase 3 study designed to assess the safety, tolerability and pharmacokinetics of temporarily switching between UPTRAVI tablets and UPTRAVI IV.

    BioSpace release

    Latest in Surgical/Critical Care

    Photo 27013405 © Hongqi Zhang (aka Michael Zhang) | Dreamstime.com
    Surgical/Critical Care

    The 3 Pillars to Reduce Healthcare Drug Diversion Among Nurses with Substance Use Disorder

    Deborah Koivula RN, BSN, CARN
    Nov. 20, 2023
    Photo 165865963 © Andrew Norris | Dreamstime.com
    Surgical/Critical Care

    FDA issues letter to healthcare providers about labeling updates for BD surgical mesh products

    Nov. 15, 2023
    Photo 1423201 | Blood © Geopappas | Dreamstime.com
    Surgical/Critical Care

    Different transfusion approaches for helping heart attack patients who develop anemia

    Nov. 13, 2023
    Photo 174063179 © Ian Wilson | Dreamstime.com
    Dreamstime Xxl 174063179
    Surgical/Critical Care

    Medtronic issues notification about stolen, defective video laryngoscopes

    Oct. 27, 2023
    175382420 © Stokkete | Dreamstime.com
    Iv Primary
    Surgical/Critical Care

    Healthcare Industry Needs Infusion of IV Products

    Brenda Silva
    Oct. 27, 2023
    Healthcare Purchasing News
    https://www.facebook.com/hpnonline
    https://www.linkedin.com/company/healthcare-purchasing-news/
    https://twitter.com/HPN_Online
    • About Us
    • Contact Us
    • Advertise
    • Do Not Sell or Share
    • Privacy Policy
    • Terms & Conditions
    © 2023 Endeavor Business Media, LLC. All rights reserved.
    Endeavor Business Media Logo